

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Schering Aktiengesellschaft :
Request for Patent Term Extension : **CERTIFICATE OF**
U.S. Patent No. 4,591,585 : **INTERIM EXTENSION**

On May 21, 2004, patent owner Schering Aktiengesellschaft, through its exclusive licensee BioMedicines Inc., timely filed an application under 35 U.S.C. § 156(d)(5) for an interim extension of the term of U.S. Patent No. 4,591,585. The patent claims the product atamestane. The application indicates that a New Drug Application for the human drug product atamestane has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially.

Review of the application indicates that except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. § 156, and that the patent should be extended for one year as required by 35 U.S.C. § 156(d)(5)(B). Since it is apparent that the regulatory review period will continue beyond the expiration date of the patent (June 18, 2004), interim extension of the patent term under 35 U.S.C. § 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. § 156(d)(5) of the term of U.S. Patent No. 4,591,585 is granted for a period of one year from the expiration date of the patent, i.e., until June 18, 2005.

6/24/04
Date

Jon W. Dudas
Jon W. Dudas
Acting Under Secretary of Commerce for Intellectual Property and
Acting Director of the United States Patent and Trademark Office